1. Mac Mahon S, Peto R,
Cutler J, et al. Blood pressure, stroke and coronary heart disease. Part 2.
Short-term reductions in blood pressure: overview of randomized drug trials in
the epidemiological context. Lancet 1990;335:827-38.
2. Houston MC. The management of hypertension and associated risk factors for
the prevention of long-term cardiac complications. J Cardiovasc Pharmacol
1993;21(Suppl 2):38-44.
3. Motz W, Vogt M, Scheler S, et al. Prevention with vasoactive drugs. Z Kardiol
1992;81(Suppl 4):199-204.
4. Gelpi RJ, Pasipoularides A, Lader AS, et al. Changes in diastolic cardiac
function in developing and stable perinephritic hypertension in conscious dogs.
Circ Res 1991;68:555-67.
5. Antony I, Nitenberg A, Foult JM. Coronary reserve is moderately reduced in
hypertensive patients without left ventricular hypertrophy and may be normalized
by antihypertensive therapy. JACC 1992;19:
392(abstr. )
6. Parodi O, Neglia D, Sambuceti G, et al. Regional myocardial blood
flow and coronary reserve in hypertensive patients. Effect of therapy. Drugs
1992;44(Suppl 1):48-55.
7. Leschke M, Schoebel PC, Vogt M, et al. Reduced peripheral and coronary
vasomotion in systemic hypertension. Eur Heart J 1992;13(Suppl D):96-9. 8. Aguirre
JM, Rodriguez E, Ruiz de Azua E, et al. Segmentary coronary reserve
in hypertensive patients with echocardiographic left ventricular hypertrophy,
gammagraphic
ischaemia and normal coronary angiography. Eur Heart J 1993;14(Suppl J):25-31.
9. Quyyuimi AA, Cannon RO III, Panza JA, et al. Endothelial dysfunction in
patients with chest pain and normal coronary arteries. Circulation
1992;86:1864-71.
10. Gaasch WH. Diastolic dysfunction of the left ventricle: importance to the
clinican. Adv Intern Med 1990;35:311-40.
11. Houghton JL, Carr AA, Prisant LM, et al. Morphologic, hemodynamic and
coronary perfusion characteristics in severe left ventricular hypertrophy
secondary to systemic hypertension and evidence for nonatherosclerotic
myocardial ischemia. Am J Cardiol 1992;69:219-24.
12. Tomanek RJ. Response of the coronary vasculature to myocardial hypertrorphy.
JACC 1990;15:528-33.
13. Strauer BE. Left ventricular hypertrophy, myocardial blood flow and coronary
flow reserve. Cardiology 1992;81:274-82.
14. Strauer BE. Development of cardiac failure by coronary small vessel disease
in hypertensive heart disease? Hypertension
1991;9(Suppl 2):s11-s22.
15. . ., . ., . ., . .
. .
1991;8:22-6.
16. Asmar R, Benetos A, Pannier B, et al. Prevalence and circadian variations of
ST-segment depression and its concomitant blood pressure changes in asymptomatic
systemic hypertension. Am J Cardiol 1996;77(5):384-90.
17. Schroeder AP, Brysting B, Sogaard P, Pedersen OL. Silent myocardial
ischaemia in untreated essential hypertensives. Blood Press 1995;4(2):97-104.
18. Siegel D, Cheitlin MD, Seeley DG, et al. Silent myocardial ischemia in men
with systemic hypertension and without clinical evidence of coronary artery
disease. Am
J Cardiol 1992;70(1):86-90.
19. . ., . ., . . .
ST .
1991;4:40-4.
20. Picaso E, Lucarini AR, Lattanri F, Marini C. ST-segment depression elicited
by dipyridamole infusion in asymptomatic hypertensive patients. Hypertension
1990;16:19-25.
21. Salcedo EE, Marwick TH, Korzick DH, et al. Left ventricular hypertrophy
sensitizes the myocadium to the development of ischemia. Eur Heart J 1990;11(Suppl
G):72-8.
22. Scheler S, Motz W, Vester J, Strauer BE. Transient myocardial ischemia in
hypertensive heart disease. Am J Cardiol 1990;65:51G-5G. 23.
. ., . ., . . . ""
. I.
. 1992;4:9-12.
24. ChinWL,
O'KellyB,
TubauJF,
etal.
Diagnostic accuracy
of exercise thallium-201 scintigraphy in men with asymptomatic essential
hypertension. Am J Hypertens 1992;5(7):465-72.
25. Jager D, Vogel A, von Dryander S, et al. The importance of 201-thallium
myocardial scintigraphy in the hypertensive patients. Dtsch Med Wochenschr
1992;117:1423-8.
26. Pringle SD, Dunn FG, Tweddel AC, et al. Silent myocardial ischemia in
hypertensive patients with left ventricular hypertrophy. Circulation
1990;82:111-63.
27. . ., . ., . .
.
1994;4:9-11.
28. Frishman WH. The interplay of ischemic and hypertensive pathophysiology on
cardiac function. J Cardiovasc Pharmacol 1991;18(Suppl 4):s17-s21.
29. Bayes-Genis A, Guindo J, Vinolas X, et al. Cardiac arrhythmias and left
ventricular hypertrophy in systemic hypertension and their influences on
prognosis. Am J Cardiol 1995;76:54D-9D.
30. Vogt M, Motz W, Scheler S, Strauer BE. Disorders of coronary
microcirculation and arrhythmias in arterial hypertension. Am J Card
1990;65:45G-50G.
31. Kennedy HL, Wiens RD, Louis St. Ambulatory(Holter) electrocardiography and
myocardial ischemia. Am Heart J 1989;117:164-76.
32. Douglas PS, Berko B, Lesh M, Reichek N. Alteration in diastolic function in
response to progressive left ventricular hypertrophy. JACC 1989;13:461-7.
33. Licata G, Scaglione R, Parinello G, Corrao S. Rapid left ventricular filling
in untreated hypertensive subjects with or without left ventricular hypertrophy.
Chest 1992;102(5):1507-11.
34. Mori C, Watanabe K, Haneda N, et al. Does left ventricular diastolic
dysfunction become a predictive index of future essential hypertension in
childhood? Shiname heart study. Hypertension 1992;10(Suppl 4):10(abstr).
35. Fleg JL , Gersterblith G, Zonnerman AB, et al. Prevalence and prognostic
significance of exercise-induced silent myocardial ischemia detected by thallium
scintigraphy and electrocardiography in asymptomatic valunteers. Circulation
1990;81:428-36.
36. Mehta JL. Emerging options in the management of myocardial ischemia. Am J
Cardiol 1994;73(3):18A-27A.
37. DeQuattro V. Individualization of therapy for hypertension in the 1990's:the
role of calcium antagonists. Clin Exper Hypertens 1994;16(6):853-64.
38. Kloner RA, Przyklenk K. Cardioprotection with angiotensin converting enzyme
inhibitors: redefined for the 1990s. Clin Cardiol 1992;15:95-103.
39. Luft FC, Haller H. Calcium channel blockers in current medical:an update for
1993. Clin
Exp Hypertens 1993;15(6):1263-76.
40. . ., . ., . . .
. 1991;10:15-7.
41. SteinbeckG.
Calciumantagonistsandsilentmyocardialischemia.
Drugs 1992;43(Suppl
1):15-20.
42. Hansson L, Dahlof B. Calcium antagonists in the treatment of
hypertension:state of the art. J Cardiovasc Pharmacol 1990;15(Suppl 4):s71-s5.
43. .
.,
.
.,
.
.
.
,
.
1992;1:47-9.
44. . ., . ., . . .
? 1991;2:12-5.
45. . ., . ., . ., . .
( ) II .
1995;9:50-3.
46. IriarteM,
CasoR,
MugraN,
etal.
Enalapril-induced
regression of hypertensive left ventricular hypertrophy, regional ischemia, and
microvascular angina. Amer J Cardiol 1995;75: 850-2.
47. Marmor AT, Rettig-Sturmer G. Antiischamische Effekte von Cilazapril bei
hypertensiven Patienten, bei denen gleichzeitig eine Angina pectoris vorliegt.
ardiology
1993;82(Suppl 2):29-31.
48. Paul M, Ganten D. The molecular basis of cardiovascular hypertrophy: the
role of the renin-angiotensin system. J Cardiovasc Pharmacol 1992;19(Suppl
5):s51-s8.
49. Evequoz D, Erne P. Betablocker in der antihypertensiven Behandlung. Schweiz
Rundsch Med Prax 1995;84(10):281-7.
50. Cruickshank JM. Beta-blockers:primary and secondary prevention. J Cardiovasc
Pharmacol 1992;20(Suppl 11):S55-869.
51. Otterstad JE. Ischaemia and left ventricular hypertrophy. Eur Heart J
1993;14(Suppl F):2-6.
52. Feuerstein GZ, Ruffolo RRJr. Carvedilol, a novel multiple action
antihypertensive agent with antioxidant activity and the potential for
myocardial and vascular protection. Eur Heart J 1995;16(Suppl F):38-42.
53. Storstein L. Diuretics, arrhythmias and silent myocardial ischaemia in
hypertensive patients. Eur Heart J
1992;13(Suppl G):81-4.